An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

NCT00720798 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2067

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Tocilizumab
DRUG: Disease-modifying anti-rheumatic drugs
DRUG: Non-steroidal anti-inflammatory drugs
DRUG: Oral corticosteroids

Sponsor

Hoffmann-La Roche